A multicentered study on efficiency of noninvasive ventilation procedures (SAFE-NIV)

Ebru Atike ONGUN1*, Oğuz DURSUN1, Ayşe Beren ANIL2, Ümit ALTUG2, Özlem TEMEL KÖKSOY3, Başak Nur AKYILDIZ4, Serkan ÖZSOYLU5, Tanıl KENDİRLİ, Serhan ÖZCAN6, Rıza Dinçer YILDIZDAŞ7, İlknur TOLUNAY8, Bülent KARAPINAR7, Mehmet Arda KILINÇ6, Demet DEMİRKOL8

1 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Akdeniz University Antalya, Turkey
2 Division of Pediatric Critical Care, Faculty of Medicine, Department of Pediatrics, İzmir Katip Celebi University and Tepecik Research and Training Hospital, İzmir, Turkey
3 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Samsun Ondokuz Mayıs University, Samsun, Turkey
4 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Erciyes University, Kayseri, Turkey
5 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey
6 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Çukurova University, Adana, Turkey
7 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Ege University, İzmir, Turkey
8 Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, İstanbul University, İstanbul, Turkey

* Correspondence: ebru_temel@yahoo.com

Background/aim: To characterize the clinical course of noninvasive positive pressure ventilation (NIPPV) and high flow humidified nasal cannula ventilation (HFNC) procedures; perform risk analysis for ventilation failure.

Material and methods: This prospective, multi-centered, observational study was conducted in 352 PICU admissions (1 month-18 years) between 2016 and 2017.

SPSS-22 was used to assess clinical data, define thresholds for ventilation parameters and perform risk analysis.

Results: Patient age, onset of disease, previous intubation and hypoxia influenced the choice of therapy mode: NIPPV was preferred in older children (p = 0.002) with longer intubation (p < 0.001), ARDS (p = 0.001), lower respiratory tract infections (p < 0.001), chronic respiratory disease, (p = 0.005), malignancy (p = 0.048) and immune deficiency (p = 0.026).

The failure rate was 13.4%. sepsis, ARDS, prolonged intubation, and use of nasal masks were associated with NIV failure (p = 0.001, p < 0.001, p < 0.001, p = 0.025). The call of intubation or re-intubation was given due to respiratory failure in twenty-seven (57.5%), hemodynamic instability in eight (17%), bulbar dysfunction or aspiration in 5 (10.6%), neurological deterioration in 4 (8.5%) and developing ARDS in 3 (6.4%) children. A reduction of less than 10% in the respiration within an hour increased the odds of failure by 9.841 times (OR: 9.841, 95% CI: 2.0021–48.3742). FiO2 > 55% at 6th hours and PRISM-3 >8 were other failure predictors. Of the 9.9% complication rate, the most common complication was pressure ulcerations (4.8%) and mainly observed when using full-face masks (p = 0.047). Fifteen (4.3%) patients died of miscellaneous causes. Tracheostomy cannulation was performed on 16 children due to prolonged mechanical ventilation (8% in NIPPV, 2.6% in HFNC)

Conclusion: Absence of reduction in the respiration rate within an hour, FiO2 requirement >55% at 6th hours and PRISM-3 score >8 predict NIV failure.

Key words: HFNC, noninvasive positive pressure ventilation, children, respiratory failure

Received: 03.04.2020 • Accepted/Published Online: 28.01.2021 • Final Version: 28.06.2021

Background/aim: To characterize the clinical course of noninvasive positive pressure ventilation (NIPPV) and high flow humidified nasal cannula ventilation (HFNC) procedures; perform risk analysis for ventilation failure.

Material and methods: This prospective, multi-centered, observational study was conducted in 352 PICU admissions (1 month-18 years) between 2016 and 2017.

SPSS-22 was used to assess clinical data, define thresholds for ventilation parameters and perform risk analysis.

Results: Patient age, onset of disease, previous intubation and hypoxia influenced the choice of therapy mode: NIPPV was preferred in older children (p = 0.002) with longer intubation (p < 0.001), ARDS (p = 0.001), lower respiratory tract infections (p < 0.001), chronic respiratory disease, (p = 0.005), malignancy (p = 0.048) and immune deficiency (p = 0.026).

The failure rate was 13.4%. sepsis, ARDS, prolonged intubation, and use of nasal masks were associated with NIV failure (p = 0.001, p < 0.001, p < 0.001, p = 0.025). The call of intubation or re-intubation was given due to respiratory failure in twenty-seven (57.5%), hemodynamic instability in eight (17%), bulbar dysfunction or aspiration in 5 (10.6%), neurological deterioration in 4 (8.5%) and developing ARDS in 3 (6.4%) children. A reduction of less than 10% in the respiration within an hour increased the odds of failure by 9.841 times (OR: 9.841, 95% CI: 2.0021–48.3742). FiO2 > 55% at 6th hours and PRISM-3 >8 were other failure predictors. Of the 9.9% complication rate, the most common complication was pressure ulcerations (4.8%) and mainly observed when using full-face masks (p = 0.047). Fifteen (4.3%) patients died of miscellaneous causes. Tracheostomy cannulation was performed on 16 children due to prolonged mechanical ventilation (8% in NIPPV, 2.6% in HFNC)

Conclusion: Absence of reduction in the respiration rate within an hour, FiO2 requirement >55% at 6th hours and PRISM-3 score >8 predict NIV failure.

Key words: HFNC, noninvasive positive pressure ventilation, children, respiratory failure

1. Introduction
The introduction of new ventilation strategies at pediatric intensive care (PICU) units broadened horizons from conventional mechanical ventilation (MV) to noninvasive ventilation (NIV) for children who require advanced respiratory support. This alternative strategy improves respiratory functions in children with acute respiratory failure (ARF) by preserving intact airway reflexes while avoiding the potential risks of endotracheal intubation [1]. Facilitating early liberation from intubation is another advantage especially for those delivering MV [2]. NIV improves oxygenation and effective ventilation by
decreasing the work of breathing and unloading respiratory muscles. The outcome is better oxygen delivery with enhanced gas exchange and better ventilation/perfusion ratio in patients with hypoxic and/or hypercapnic ARF [3,4]. The efficiency has been studied in several clinical conditions including acute pneumonia [5], bronchiolitis [6], status asthmaticus [7] and post-extubation respiratory failure [8]. Physiological studies also confirm the positive influence on respiratory functions [9,10].

Noninvasive positive pressure ventilation (NIPPV) techniques include continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP). They are used in various etiologies [11–13] and the decision of modality depends on the nature of respiratory failure: CPAP for hypoxic ARF and smaller children, BiPAP for older children with hypoxic and/or hypercapnic ARF [14]. Although not classified as positive pressure ventilation, high flow humidified nasal cannula ventilation (HFNC) is gaining interest in pediatric practice and is presented as an alternative to CPAP in infants. HFNC enhances oxygenation by providing anatomic oxygen reservoirs and washing out the dead airway space [14]. It drives a CPAP-like effect at 6 L/min by generating a positive pressure through the respiratory cycle [14,15].

NIV success relies upon appropriate patient selection, choice of modality and experienced trained staff [14]. In contrary to adult consensus conference statements [2,16], the guideline addressing the clinical applications (criteria for initiation and/or discontinuation) in children remain limited in this manner [17]. The decision of failure is mostly left to the discretion of the treating physician. Moreover, there is a varying range of discrepancy in inter-unit ventilation strategies between health-care facilities [17]. This prospective, multicenter, observational study was planned to characterize the clinical course of NIPPV and HFNC implementations and observe success rates in decreasing the necessity of mechanical ventilation or re-intubation. The secondary outcome is to assess risk analysis for respiratory failure and examine therapy-attributed complications (if any).

2. Materials and methods
The study was conducted with the collaboration of eight PICUs (universities or teaching hospitals governed by the ministry of health) all across the country between December 2016 and December 2017. The approval of the local ethical committee was obtained from Akdeniz University Faculty of Medicine, Clinical Research Ethics Committee (no: 70904504/525, date: 11.18.2016). The study was also registered at clinicaltrials.gov (approval number: 70904504/525). All critically-ill children from 1 month to 18 years requiring NIPPV or HFNC in the intensive care settings were enrolled in this study. We did not set any criteria for NIPPV or HFNC institution, therapy discontinuation and the call of intubation. The clinical decisions were led by the discretion of the attending senior physician at each center.

A three-page case report form (CRF) was designed to collect data. The patient demographics were grouped according to the patient age (infants less than 12 months, toddlers/preschool-aged children between 13 and 60 months, school-age/adolescents between 61 months to 18 years) and the underlying disease (including acute and chronic settings). We categorized acute disease as i) lower respiratory tract infections (LRTI) ii) conditions related to bronchospasm including bronchiolitis and asthma attacks, iii) upper respiratory tract infection (URT): laryngitis and laryngotracheobronchitis (croup), iv) central nervous system (CNS) related disease: any disorder resulting in an incapability to sustain airway maneuvers, vi) sepsis, vii) ARDS defined by the Pediatric Acute Lung Injury Consensus Conference Group (PALICC) [18], and finally vii) postoperative laryngeal stridor. The underlying chronic conditions were classified by Feudtner's coding system [19]. The second page has consisted of a multi-colon table to record the respiratory rate (RR), heart rate (HR), systemic, mean and diastolic blood pressures (BP), the pediatric risk of mortality-3 score (PRISM-3) and pediatric logistic organ dysfunction score (PELOD), Glasgow coma scale (GCS), comfort score, and blood gas parameters. The device mode and settings, types of masks used and drugs used for sedation (if given) were obtained. We adjusted RR nd HR for age above the 99th percentile to determine the abnormality above normal limits to define tachypnea and tachycardia [20]. Data were collected up to 5 days: immediately before commencing respiratory support, at 1st, 2nd, 6th, 24th, 48th hours, then daily. However, the statistical analysis regarding NIV failure involved the first 48 h. The clinical outcome including the cause of intubation or re-intubation (if so the timing of intubation), the complications, the length of ventilation therapy, PICU stay and hospitalization were also recorded.

Children were divided into two main groups whether if they achieved therapy success or not. Therapy failure was defined as the necessity of endotracheal intubation or re-intubation within the study period. In case of a failed trial, the collaborators were asked to define the cause of failure as patient-ventilator asynchrony, use of misfit interface, excessive air leaks, neurological deterioration (GCS < 8 or deterioration over three units), risk of aspiration or bulbar dysfunction (loss of swallowing), hemodynamic alterations, presence of arrhythmia, pneumothorax, and progression to ARF (worsening respiratory condition). The definition of ARF was adapted from the criteria of Teaque as an unsustainable alveolar exchange to meet the
metabolic cellular demands [12]. CRF has also consisted of several failure risk factors previously defined in the literature, to set up criteria to anticipate ARF such as PaO$_2$/FiO$_2$ < 200 [5,21] or FiO$_2$ necessity over 80% at 1st hour [22], blood gas pH < 7.25 after 2 h [23], failure to achieve a decrease in RR within 6 h, clinically observed increased work of breathing (respiratory score of 1–2 by Monachan’s pediatric early warning system) [24], progression to moderate/severe ARDS (oxygenation index > 8) [18].

Subgroup analyses were performed depending on the mode of therapy and the therapy implementation (first-line therapy or rescue therapy). HFNC failures consisted of children who delivered HFNC as respiratory support throughout the study and encountered intubation or reintubation.

2.1. Statistical analysis
IBM SPSS Statistics for Windows, v. 22.0 (IBM Corp., Armonk, NY, USA) was used for statistics. Pearson chi-square and Fisher’s exact test were used to assess categorical data; Mann–Whitney U test and Student’s t-test for nonparametrically distributed continuous variables (after performing Shapiro–Wilks test to control normality assumptions) We used repeated-measures ANOVA with posthoc Bonferroni test to analyze the change in the means of continuous variables at different time points. The Friedman test alongside the Bonferroni correction were used for nonparametric comparison of parameters measured at different times. The receiver operating characteristic (ROC) curve analysis was applied to identify the cut-off points of continuous variables with significant differences between groups and the Youden index to determine the optimal cutoff point of each variable of interest. Continuous variables were then classified into positive or negative groups according to the cutoff point. We then, performed a multivariate logistic regression analysis to determine independent risk factors associated with therapy failure. Data are expressed as n (%), mean ± standard deviation (SD), or median (minimum-maximum). P-value < 0.05 was considered statistically significant.

3. Results
3.1. Patient characteristics
A total of 352 children of male gender predominance (56.8%) with a median age of 18 months (1.5–204 months) and the bodyweight of 10 kg (min-max: 2.1–120 kg) was enrolled in the study. The distribution of age category was infancy in 152 patients (43.2%), toddlers/preschool era in 119 (33.8%) patients and school-age/adolescents in 81 (23%) patients. LRTI and hypoxic ARF were the common causes of NIV administration (47.4%, 67.9%; Table 1). Overall, 71.6% of the population had an underlying chronic condition involving (in decreasing order) cardiac disease, neurological conditions, and immune deficiency (25.6%, 21.9%, 7.1%; Table 2). The median duration of NIV administration was 72 h (min-max: 36–120 hours).

3.2. Decision of modality and device selection
Table 3 presents the population demographics and outcome measures according to treatment modality. Both NIPPV and HFNC were used as first-line or rescue therapy (rescue therapy: 48.8% versus 58.1%, p = 0.092). Several factors acted upon the selection of ventilation mode such as, patient age, duration of previous intubation, the nature of acute and chronic disease. NIPPV was the preferred modality in older children with longer intubation periods (p = 0.002, p < 0.001), in an acute setting of ARDS and LRTI (p = 0.001, p < 0.001) and in an underlying condition such as chronic respiratory disease, malignancy and immune deficiency (p = 0.005, p = 0.048, p = 0.026). The choice of method were based on the degree of age-adjusted tachypnea (NIPPV: 65.3%, HFNC: 52.9%, p = 0.022) and SpO$_2$/FiO$_2$ values (NIPPV: 175.24 ± 52.99, HFNC: 192.83 ± 55.23; p = 0.005), instead of blood gas pCO$_2$ (NIPPV: 45.39 ± 11.01 mmHg, HFNC: 43.55 ± 9.54 mmHg, p = 0.144).

The children delivering NIPPV were more likely to receive treatment via specific noninvasive ventilation devices (93.6%) with full-face masks (48%), nasal masks (19.2%), and oronasal masks (11.2%).

3.3. Sedation procedures and complications
To optimize care, 46.9% of children received a sedation procedure under assessment of comfort scores (Table 1). The most frequent drugs were dexmedetomidine, ketamine, and midazolam administered at intermittent bolus doses (32.1%, 30.3%, and 30.3% respectively). Sedation sessions were applied to children using (in decreasing order), full-face masks 55%, nasal masks 45.8%, nasal prong 45.3%, and oronasal masks 42.9%.

A total of 35 (9.9%) complications were observed regardless of therapy mode (NIPPV: 14.4% vs. HFNC: 7.5%; p = 0.063). The incidence varied between different mask types: 25% in nasal masks, 11.7% in full-face masks, 8.3% in nasal prongs and 7.1% in oronasal masks. The most common complication was pressure ulcerations (skin/mucosa breakdown) (17/352, 4.8%). The ones who failed their NIV sessions had increased complication rates (p < 0.001).

3.4. Therapy failure and risk analysis
Forty-seven (13.4%) children were marked as NIV failures and the majority had to be intubated within 48 h (in 4 children, the decision of failure extended beyond 48 h: one in NIPPV and 3 in HFNC). Instead of the patient characteristics (age, sex), the nature of acute respiratory failure (hypoxic or hypercapnic), NIV modality (NIPPV/HFNC) or the therapy institution (first-line/rescue therapy), the acute onset of disease (sepsis and ARDS: p = 0.001, p < 0.001) and the underlying chronic conditions
(metabolic and genitourinary problems: \( p = 0.017 \), \( p = 0.048 \)) were related to NIV failure (Table 4). These patients had longer intubation period prior to NIV administration, higher PRISM-3, PELOD scores and lower GCS (\( p < 0.001 \), \( p < 0.001 \), \( p < 0.001 \), \( p = 0.003 \), respectively). The call of intubation/re-intubation was given due to respiratory failure in 27 (57.5%) children, hemodynamic instability in 8 (17%), bulbar dysfunction or aspiration in 5 (10.6%) children, neurological deterioration in 4 (8.5%) children and developing ARDS in 3 (6.4%) children. The use of a nasal mask during NIPPV was also associated with NIV failure (15.2% versus 5.6%; \( p = 0.025 \)).

\[\text{Table 2. Acute and Chronic Onset of Diseases}\]

| Acute onset of disease | The underlying chronic conditions |
|------------------------|----------------------------------|
| LRTI                   | 167 (47.4%)                     |
| Bronchiolitis/asthma attack | 61 (17.3%)                      |
| URTI                   | 12 (3.4%)                       |
| Postoperative stridor  | 12 (3.4%)                       |
| Heart failure          | 41 (11.6%)                      |
| Sepsis                 | 30 (8.5%)                       |
| CNS-related            | 21 (6%)                         |
| ARDS                   | 13 (3.7%)                       |

| The underlying chronic conditions | |
|-----------------------------------|----------------------------------|
| Cardiac disease *                 | 90 (25.6%)                       |
| Neurological conditions           | 77 (21.9%)                       |
| immune deficiency                 | 25 (7.1%)                        |
| Metabolic disease                 | 22 (6.3%)                        |
| Respiratory disease *             | 20 (5.7%)                        |
| Genetic                            | 19 (5.4%)                        |
| Genitourinary                      | 16 (4.5%)                        |
| Malignancy                         | 11 (3.1%)                        |
| Gastrointestinal disease *        | 9 (2.6%)                         |

Abbreviations: LRTI: lower respiratory tract infection, URTI: upper respiratory tract infection, CNS-related: central nervous system related disease, ARDS: acute respiratory distress syndrome

*Cardiac disease includes congenital heart disease; Respiratory disease includes bronchopulmonary dysplasia; Gastrointestinal disease involves hepatic and biliary system
Figures 1 and 2 present the vital parameters and blood gas analysis in NIV failure (Figure 1a: Respiration rate, Figure 1b: Heart rate, Figure 1c: Systolic blood pressure, Figure 1d: Diastolic blood pressure, Figure 1e: Glasgow coma scale, Figure 1f: Comfort score; Figure 2a: SpO$_2$/FiO$_2$, Figure 2b: PaO$_2$/FiO$_2$, Figure 2c: Blood gas pH, Figure 2d: Blood gas pCO$_2$ in NIV Failure). NIPPV failures displayed significant device settings: higher inspiratory pressure (IPAP) requirement with lower tidal volumes at all times (Table 5). On the contrary, the initial settings of flow-rates in HFNC remained more or less the same regardless of therapy success (p = 0.973).

ROC curve analysis for NIV failure has indicated the cutoff values (calculated by the Youden index) for FiO$_2$ >55% at the 6th hour and PRISM-3 score >8 (AUC: 0.762, 95% CI: 0.710–0.809, sensitivity 89.87%, specificity 70.79% and AUC: 0.756, 95% CI:0.695–0.810, sensitivity: 86%, specificity: 77.2%). A multivariate logistic regression was launched to define the deteriorating child at risk for NIV failure and included the variables such as respiration rate, FiO$_2$ at the 6th hour, PRISM-3 score, ARDS, sepsis, and metabolic and genitourinary disease. The model identified a less than 10% decrease in respiration in the 1st hour (OR: 9.841, 95% CI: 2.002–48.374, p < 0.004), FiO$_2$ necessity >55% at 6th hours (p = 0.002, OR: 5.2936 95% CI: 1.7964–15.5995, p = 0.002) and PRISM-3 score >8 as independent risk factors for NIV failure OR: 3.9011 95% CI: 1.3370–11.3827, p = 0.012).

3.5. Prognosis
Of forty-seven (13.4%) ventilation failures, 15 (4.3%) children died of miscellaneous causes (time of death: median 15.5 days, min-max: 4–32 days). Tracheostomy cannulation was performed on 16 children due to prolonged invasive mechanical ventilation (8% in NIPPV, 2.6% in HFNC).

4. Discussion
There were several outcomes in the current study. The immediate effect of noninvasive ventilation on patients’ respiration was observed at the very early stages of therapy: the successful trials were able to lower down their RR at least 10% within an hour. The changes in ventilation parameters appeared to be a significant indicator to observe therapy response [25]. In a previous study from Bakalli et al., children achieved success with a positive predictive value of 88.2% (95% CI: 72.5%–96.6%), when

Table 3. The descriptive analysis of NIV modalities (HFNC–NIPPV).

|                      | NIPPV | HFNC | o     | NIPPV | HFNC | p        |
|----------------------|-------|------|-------|-------|------|----------|
| Age (months)*        | 27 (1.5–204) | 14 (1.5–192) | **0.002** | Bodyweight (kg)* | 10.5 (3–120) | 9.2 (2–100) | **0.004** |
| Infant               | 46 (36.8%) | 106 (46.7%) | **0.017** | NIV duration (hours)* | 72 (6–480) | 52 (6–48024) | **0.012** |
| Toddlers/Preschool   | 36 (28.8%) | 83 (36.6%) | **0.001** | Previous intubation (hours)* | 140 (28–726) | 48 (25–1000) | < **0.001** |
| School age/adolescents | 43 (34.4%) | 38 (16.7%) | **0.569** | PRISM-3 score* | 6 (2–38) | 5 (2–51) | 0.264 |
| Male gender, (n)     | 72 (57.6%) | 128 (56.4%) | **0.826** | PELOD score* | 6 (2–31) | 8 (2–50) | 0.240 |
| Acute onset of disease |          |          |        | Underlying chronic conditions |          |          |        |
| LRTI                 | 76 (60.8%) | 91 (40.1%) | < **0.001** | Cardiac disease | 19 (15.2%) | 71 (31.1%) | **0.001** |
| Bronchiolitis/asthma | 43 (34.4%) | 108 (47.6 %) | **0.017** | Neurological condition | 33 (26.4%) | 44 (19.4%) | 0.128 |
| URTI                 | 11 (4.8%) | 16 (4.8%) | **0.012** | Metabolic disease | 12 (9.6%) | 10 (4.4%) | **0.054** |
| Postoperative stridor| 4 (3.2%) | 8 (3.5%) | **0.001** | Respiratory disease | 6 (4.8%) | 13 (5.7%) | 0.713 |
| ARDS                 | 10 (8%) | 3 (1.3%) | **0.001** | Genitourinary disease | 13 (10.4%) | 7 (3.1%) | **0.005** |
| Heart failure        | 10 (8%) | 31 (13.7%) | 0.113 | Gastrointestinal disease | 6 (4.8%) | 10 (4.4%) | 0.865 |
| Sepsis               | 10 (8.8%) | 19 (8.4%) | 0.894 | Malignancy | 7 (5.6%) | 4 (1.8%) | **0.048** |
| CNS-related          | 5 (4%) | 16 (7%) | 0.248 | Immune deficiency | 14 (11.2%) | 11 (4.8%) | **0.026** |
| Outcome              |          |          |        |                  |          |          |        |
| PICU stay (days)*    | 11 (2–98) | 7 (2–69) | < **0.001** | Hospital discharge (days)* | 20 (5–98) | 12 (4–95) | < **0.001** |
| Tracheostomy (n)     | 10 (8%) | 6 (2.6%) | **0.021** | Exitus, (n) | 8 (6.4%) | 7 (3.1%) | 0.140 |

*median (min-max). Abbreviations; NIPPV: noninvasive positive pressure ventilation, HFNC: high flow humidified nasal cannula ventilation, LRTI: lower respiratory tract infection, URTI: upper respiratory tract infection, ARDS: acute respiratory distress syndrome, CNS related: central nervous system related, PICU: pediatric intensive care unit.
they were able to reduce their RR more than 10 respiration/min in 2 h [25]. Similarly, Mayordomo-Colunga et al. stated the absence of RR decline at 1st and 6th hours in NIPPV failure [26]. Several models also predict HFNC failure such as RR above the 90th percentile for age at triage [1,27], no RR or HR change within 60 min [28] and worsening pediatric early warning scores [29]. The failure rate (13.4%) in this study was within the reported ranges of 3% and 30% [3,8,30]. Neither the treatment modality (NIPPPV/HFNC) nor the therapy institution (first-line/rescue therapy) was associated with NIV failure. Literature data suggest that longer intubation [3], higher FiO₂ requirement [3,5,31], PRISM-3 and PELOD scores [31], hypoxic ARF, parenchymal lung disease and ARDS [3,5,25,32] are recognized as potential risk factors. However all of the published researches report different cutoff values other than thresholds obtained in the current study (PRISM-3 score > 8 and FiO₂ requirement > 55 at

Table 4. The descriptive analysis of NIV failure.

| Variable                        | NIV failure | NIV success | p   | Variable                        | NIV failure | NIV success | p   |
|---------------------------------|-------------|-------------|-----|---------------------------------|-------------|-------------|-----|
| Age (months)*                   | 36 (2–192)  | 16 (1.5–204)| 0.137 | PRISM-3 score*                  | 13 (2–51)   | 5 (2–36)    | <0.001 |
| Bodyweight (kg)*                | 12 (2.1–60) | 9.7 (2.7–120)| 0.453 | PELOD score*                    | 14 (2–50)   | 6 (2–44)    | <0.001 |
| Male gender                     | 28 (59.6%)  | 172 (56.4%) | 0.682 | GCS (mean ± SD)                 | 13.21 ± 1.67| 13.85 ± 1.66| 0.003 |
| Hypoxic ARF                     | 34 (72.3%)  | 205 (67.2%) | 0.483 | Complications                   | 15 (31.9%)  | 20 (6.6%)   | <0.001 |
| Acute onset of disease          |             |             |      | Acute onset of disease          |             |             |      |
| LRTI                            | 25 (53.2%)  | 142 (46.6%) | 0.397 | Cardiac                         | 4 (8.5%)    | 86 (28.2%)  | 0.004 |
| Bronchiolitis/asthma            | 1 (2.1%)    | 60 (19.7%)  | **0.003** | Neuromuscular                   | 15 (31.9%)  | 62 (20.3%)  | 0.074 |
| URTI                            | -           | 11 (3.6%)   |      | Metabolic                       | 7 (14.9%)   | 15 (4.9%)   | 0.17 |
| ARDS                            | 6 (12.8%)   | 7 (2.3%)    | <0.001 | Genetic                         | 3 (6.4%)    | 16 (5.2%)   | 0.478 |
| Heart failure                   | 4 (8.5%)    | 37 (12.1%)  | 0.471 | Respiratory                     | 3 (6.4%)    | 17 (5.6%)   | 0.515 |
| Sepsis                          | 11 (23.4%)  | 19 (6.2%)   | 0.001 | Genitourinary                   | 5 (10.6%)   | 11 (3.6%)   | 0.048 |
| CNS-related                     | 5 (10.6%)   | 16 (5.2%)   | 0.132 | Gastrointestinal                | 3 (6.4%)    | 6 (2.0%)    | 0.105 |
| Postoperative stridor           | -           | 12 (3.9%)   |      | Malignancy                      | 3 (6.4%)    | 8 (2.6%)    | 0.170 |
| Therapy mode                    |             |             |      | Therapy implementation          |             |             |      |
| NIPPV                           | 22 (46.8%)  | 103 (33.8%) | 0.082 | First-line therapy              | 22 (46.8%)  | 137 (44.9%) | 0.808 |
| HFNC                            | 25 (53.2%)  | 202 (66.2%) |      | Rescue therapy                  | 25 (53.2%)  | 168 (55.1%) |      |
| Device selection                |             |             |      | Device selection                |             |             |      |
| Specific NIPPV device           | 18 (38.3%)  | 98 (32.1%)  | 0.072 | Interfaces                      |             |             |      |
| MV with NIV mode                | 3 (6.4%)    | 5 (1.6%)    |      | Nasal mask                      | 7 (15.2%)   | 17 (5.6%)   | 0.025 |
| Specific HFNC device            | 26 (55.3%)  | 202 (66.2%) |      | Oronasal mask                   | 3 (6.5%)    | 11 (3.6%)   | 0.408 |
| Signs of respiratory failure    |             |             |      | Full-face mask                  | 11 (23.9%)  | 50 (16.4%)  | 0.210 |
| Tachypnea*                      | 33 (70.2%)  | 167 (55.1%) | 0.052 | Nasal Prong                     | 27 (57.4%)  | 227 (74.4%) | 0.016 |
| SpO₂/FiO₂ < 200 (1st hour)      | 38 (82.6%)  | 148 (49.3%) | <0.001 | Hospitalization*                | 32 (4–98)   | 13 (5–98)   | <0.001 |
| SpO₂/FiO₂ > 80% (1st hour)      | 14 (37.8%)  | 27 (9.6%)   | <0.001 |                      |             |             |      |
| The length of stay (days)       |             |             |      |                      |             |             |      |
| PICU stay*                      | 26 (4–98)   | 7 (2–87)    | <0.001 |                      |             |             |      |
| *median (min-max); ** Age-adjusted tachypnea; Abbreviations: NIV: noninvasive ventilation, ARF: acute respiratory failure, NIPPPV: noninvasive positive pressure ventilation, HFNC: high flow humidified nasal cannula ventilation, GCS: Glasgow coma scale, LRTI: lower respiratory tract infection; URTI: upper respiratory tract infection, ARDS: acute respiratory distress syndrome, CNS-related: central nervous system related, MV with NIV mode: conventional mechanical ventilation with noninvasive ventilation mode, RR: respiration rate, PICU: pediatric intensive care unit
Figure 1. a) Respiration rate in NIV failure; b) Heart rate in NIV failure; c) Systolic blood pressure in NIV failure; d) Diastolic blood pressure in NIV failure; e) Glasgow coma scale in NIV failure; f) Comfort score in NIV failure.
Our findings were lower than previous data: a cut-off level of 10 for PRISM-3 in Bakalli’s research [25] or FiO₂ > 80% in the first hour [22], FiO₂ > 57% [5], and FiO₂ > 60% [25]. Unlike literature data reporting pneumonia as the sole factor for NIV failure [2,3], our findings pointed out sepsis and ARDS. The impact of sepsis is a little-known subject (mostly studied in malignancies) in the acute setting of NIV [33–36]. ARDS, on the other hand, is a well-defined challenge for therapy success [31]. In 2015, the PALICC group stated the beneficiary effects of noninvasive ventilation especially for an immune-compromised child under the condition of close monitoring and presence of trained healthcare providers. However, the recommendations were limited to the early ARDS stages; they concluded not to delay intubation in case of severe disease or no clinical improvement [18]. The current study’s ARDS rates were relatively lower: 8% in NIPPV, 1.3% in HFNC sessions and approximately half of the patients had to be intubated following the NIV-course (46.2%, 6/13). Yet, our findings could not be attributed to true incidence of ARDS due to the study’s observational design. Further, larger scaled investigations are needed to focus on ARDS and noninvasive ventilation.

Distinct characteristics regarding device settings emerged from this study. Despite a steady IPAP increase, 6 hours).
Table 5. The device settings in NIV failure.

| Variables | Therapy failure | Therapy success | p     |
|-----------|-----------------|-----------------|-------|
|           | Time            | Mean ± SD       | Mean ± SD |     |
| NIPPV Therapy |                 |                 |       |     |
| IPAP      |                 |                 |       |     |
| Time      | Initial         | 15.63 ± 4.73    | 12.77 ± 4.19 | 0.013 |
|          | 1. hour         | 15.88 ± 4.99    | 12.38 ± 3.21 | 0.006 |
|          | 2. hour         | 17.01 ± 5.26    | 12.93 ± 4.06 | 0.002 |
|          | 6. hour         | 16.44 ± 5.44    | 13.03 ± 4.03 | 0.015 |
|          | 24. hour        | 17.01 ± 5.82    | 12.88 ± 4.12 | 0.007 |
|          | 48. hour        | 18.80 ± 5.29    | 12.64 ± 4.48 | 0.001 |
| p         | < 0.001         | 0.200           |       |     |
| EPAP /PEEP |                 |                 |       |     |
| Initial   | 5.58 ± 0.84     | 5.57 ± 1.07     | 0.923 |     |
| 1. hour   | 5.61 ± 0.78     | 5.57 ± 0.99     | 0.705 |     |
| 2. hour   | 5.71 ± 1.21     | 5.62 ± 1.07     | 0.913 |     |
| 6. hour   | 5.59 ± 0.87     | 5.68 ± 1.09     | 0.993 |     |
| 24. hour  | 5.80 ± 1.08     | 5.67 ± 1.15     | 0.555 |     |
| 48. hour  | 5.82 ± 0.87     | 5.77 ± 1.15     | 0.676 |     |
| p         | 0.999           | 0.853           |       |     |
| FiO₂ (%)  |                 |                 |       |     |
| Initial   | 68.89 ± 22.20   | 55.98 ± 17.76   | < 0.001 |     |
| 1. hour   | 64.12 ± 18.05   | 50.54 ± 11.21   | < 0.001 |     |
| 2. hour   | 56.25 ± 13.60   | 49.46 ± 9.91    | < 0.001 |     |
| 6. hour   | 59.41 ± 14.78   | 49.13 ± 9.45    | < 0.001 |     |
| 24. hour  | 58.93 ± 16.66   | 48.35 ± 9.72    | < 0.001 |     |
| 48. hour  | 56.50 ± 7.47    | 45.06 ± 8.24    | < 0.001 |     |
| p         | 0.257           | < 0.001         |       |     |
| Inspiration time |                 |                 |       |     |
| Initial   | 0.66 ± 0.24     | 0.64 ± 0.22     | 0.819 |     |
| 1. hour   | 0.66 ± 0.25     | 0.65 ± 0.22     | 0.906 |     |
| 2. hour   | 0.68 ± 0.25     | 0.65 ± 0.22     | 0.722 |     |
| 6. hour   | 0.63 ± 0.20     | 0.64 ± 0.22     | 0.852 |     |
| 24. hour  | 0.62 ± 0.19     | 0.66 ± 0.21     | 0.551 |     |
| 48. hour  | 0.69 ± 0.18     | 0.67 ± 0.21     | 0.814 |     |
| p         | 0.999           | 0.416           |       |     |
| Rise time |                 |                 |       |     |
| Initial   | 2.68 ± 1.47     | 2.51 ± 1.45     | 0.801 |     |
| 1. hour   | 2.68 ± 1.47     | 2.57 ± 1.54     | 0.954 |     |
| 2. hour   | 2.65 ± 1.53     | 2.56 ± 1.52     | 0.961 |     |
| 6. hour   | 2.78 ± 1.53     | 2.57 ± 1.51     | 0.792 |     |
| 24. hour  | 2.73 ± 1.63     | 2.54 ± 1.54     | 0.873 |     |
| 48. hour  | 2.1 ± 1.28      | 2.37 ± 1.56     | 0.752 |     |
| p         | 0.999           | 0.416           |       |     |
| Tidal volume (mL/kg) |             |                 |       |     |
| Initial   | 6.76 ± 1.86     | 7.81 ± 1.81     | 0.049 |     |
| 1. hour   | 7.04 ± 1.69     | 7.83 ± 1.88     | 0.138 |     |
| 2. hour   | 6.62 ± 1.69     | 7.81 ± 1.72     | 0.025 |     |
| 6. hour   | 6.59 ± 1.67     | 7.81 ± 1.64     | 0.017 |     |
| 24. hour  | 6.74 ± 1.28     | 7.85 ± 1.64     | 0.034 |     |
| 48. hour  | 7.05 ± 1.55     | 7.74 ± 1.37     | 0.387 |     |
we noted steady end-expiratory pressure (EPAP/PEEP) levels in children receiving NIPPV even if they demanded higher oxygen to improve work of breathing. EPAP and PEEP are two synonymous parameters known to minimize alveolar collapse and improve oxygenation [4]. Apparently, the choice of intervention favored endotracheal in hypoxic patients instead of elevating EPAP/PEEP elevation in hypoxic patients. We think this outcome might be the reflection of PALICC recommendations on ARDS ‘not delaying intubation in the absence of clinical improvement’ [18].

Age, length of previous intubation, underlying conditions (acute and chronic settings) were noted to play a role in the decision of ventilation modality. HFNC was the preferred method of NIV in smaller children acquiring upper respiratory system problems and bronchiolitis/asthma attacks. NIPPV, on the other hand, was mostly used in older children with prolonged intubations, primary parenchymal lung disease (pneumonia, ARDS, chronic lung disease), malignancy, and immune deficiency. Complex chronic conditions inevitably influence the ventilation strategies [8,19,33]. SCARF (early CPAP in

Table 5. (Continued).

|               | p     | 0.448 | 0.752 |
|---------------|-------|-------|-------|
| Leakage       |       |       |       |
| Initial       | 20.31 ± 12.21 | 29.88 ± 18.83 | 0.076 |
| 1. hour       | 20.31 ± 12.04 | 27.9 ± 17.69   | 0.200 |
| 2. hour       | 22.07 ± 12.64 | 30.12 ± 18.82  | 0.194 |
| 6. hour       | 23.43 ± 14.52 | 29.26 ± 18.93  | 0.478 |
| 24. hour      | 27.42 ± 16.75 | 28.61 ± 18.44  | 0.927 |
| 48. hour      | 22.63 ± 13.42 | 29.83 ± 19.59  | 0.350 |
| p             | 0.413 | 0.570 |

|               |       |       |       |
| Mandatory rate|       |       |       |
| Initial       | 23.44 ± 5.40 | 22.45 ± 6.40 | 0.677 |
| 1. hour       | 24.33 ± 7.30 | 22.0 ± 5.46  | 0.502 |
| 2. hour       | 22.36 ± 4.94 | 21.54 ± 5.26 | 0.727 |
| 6. hour       | 25.31 ± 8.01 | 21.3 ± 4.78  | 0.146 |
| 24. hour      | 24.55 ± 9.06 | 20.8 ± 4.55  | 0.355 |
| 48. hour      | 24 ± 8.07   | 20.7 ± 4.51  | 0.350 |
| p             | 0.304 | 0.283 |

|               |       |       |       |
| HFNC therapy  |       |       |       |
| Flow rate     |       |       |       |
| Initial       | 17.27 ± 7.83 | 17.29 ± 7.80 | 0.973 |
| 1. hour       | 18.42 ± 8.71 | 17.79 ± 7.78 | 0.739 |
| 2. hour       | 18.01 ± 7.08 | 17.68 ± 7.62 | 0.529 |
| 6. hour       | 19.67 ± 8.71 | 17.03 ± 7.59 | 0.085 |
| 24. hour      | 20.90 ± 9.62 | 15.64 ± 7.12 | 0.008 |
| 48. hour      | 20.88 ± 10.11 | 14.39 ± 7.43 | 0.007 |
| p             | 0.027 | < 0.001 |

|               |       |       |       |
| FiO₂ (%)      |       |       |       |
| Initial       | 67.63 ± 18.59 | 50.73 ± 14.42 | < 0.001 |
| 1. hour       | 68.75 ± 19.96 | 49.88 ± 14    | < 0.001 |
| 2. hour       | 67.35 ± 18.72 | 48.64 ± 12.94 | < 0.001 |
| 6. hour       | 68.01 ± 18.59 | 47.78 ± 12.15 | < 0.001 |
| 24. hour      | 60.77 ± 20.9 | 43.36 ± 10.99 | 0.002 |
| 48. hour      | 62.78 ± 19.54 | 41.29 ± 10.54 | < 0.001 |
| p             | 0.182 | < 0.001 |

Abbreviations: ARF: acute respiratory failure, NIPPV: noninvasive positive pressure ventilation, IPAP: inspiratory positive airway pressure, EPAP: expiratory positive airway pressure, PEEP: positive end expiratory pressure, FiO₂: fraction of inspired oxygen, HFNC: high flow humidified nasal cannula ventilation.
acute respiratory failure) study is a recent, randomized, controlled study performed in children with a high-risk combination of impaired immunity and ARF [37]. Given the evidence from SCARF study, NIPPV remained as a reserved ventilation method for more distressed population with malignancy or immune deficiency who possess greater risks for endotracheal intubation. Our findings shared a common ground with the SCARF study: NIPPV was chosen for more tachypneic and hypoxic (lower SpO₂/FiO₂) children who required higher FiO₂ and longer therapy sessions in the study centers. Of note, children receiving NIPPV were more likely to require tracheostomy cannulation when they were intubated or re-intubated, even their initial PRISM-3 or PELOD scores were similar. This outcome verified the fact that, the nature of underlying problem were more important when compared to disease severity. The findings were also supported by two previous investigations that demonstrated any insignificance between PIM-2 scores and ventilation failure [22,33].

NIPPV implementations confront certain challenges amongst the youth such as air leakages, higher respiration rates, and reduced respiratory efforts to achieve patient-device synchrony. Therefore, the success depends on the appropriate device selection, including interface, circuit, device, and device settings [12]. Our local practices favored the application of specific noninvasive ventilator devices (capable of compensating high leakage) with the use of full-face masks. Recent advances in the manufacturing industry have resulted in different-sized masks, which enable more applicable, patient-friendly utilization at all ages [8]. Full-face masks provide both comfort (by spreading the mask-fit pressure over a larger surface beyond the nose) and fewer pressure-related complications than oronasal masks [12]. Besides, the efficiency are shown in terms of breathing pattern and gas exchange as much as the oronasal masks [12]. The practice regarding the selection of interfaces in the current study was consistent with the PALICC group who have suggested the application of full-face or oronasal masks in pediatric ARDS for effective ventilation [18].

Several studies emphasized the impact of nasal masks [12,38]. These masks are noted to have several advantages such as more comforting patient-friendly use, fewer gastric distension, better feeding tolerance, safer for aspiration [12], and lower risks of NIV failure [38]. Opposing this hypothesis, we observed significant complication and failure rates with the use of nasal masks. One possible explanation might be the mouth breathing of the youngster as a result of frequent nasal obstruction caused by viral infection and inflammation that could limit the efficacy of noninvasive ventilation.

The total complication rate was 9.9%. Surprisingly, they occurred mostly in failure trials instead of successfully-managed children who received ventilation support for more extended periods. Altered consciousness due to hypoxemia or hypercapnia, immobility and hemodynamic alterations in critically-ill children might be the underlying cause of this outcome. Skin/mucosa breakdown appeared to be the most common complication overall (4.8%), mainly observed at full-face masks. The incidence was within the reported range between 4% and 27% [4,39].

The study had several limitations. First of all, the scope of this research consisted of clinical observations on ventilation techniques and daily implementations. Thus we did not set any criteria for the decision of therapy institution or NIV failure. The call of intubation might have created subjectivity due to individual approaches of the collaborators. Secondly, we did not gather information on the decision-making process of the attending physicians to make any assumptions (e.g., the underlying factors for low ARDS percentage or the absence in EPAP/PEEP change throughout the ventilation session). The data on sedation sessions were also limited; whether if they were based on sedation protocols at each participating PICU or not. Despite the limitations, the prospective, observational, multi-centered nature of the study enabled us to observe the daily practice of NIV implementations and interpret a wide range of variations at multiple PICUs. The study also allowed us to improve our knowledge of ventilation techniques and to design local protocols to identify the ones at risk for developing respiratory failure. Furthermore, NIV failure was defined as intubation or re-intubation within 48 h [6]. Five days of study period has given the opportunity to observe whether the decision of failure has extended over 48 h or not. Only 4 children have failed their ventilation sessions after 48 h, therefore the statistics have included the first two days of the ventilation sessions.

5. Conclusion
Age, acute disease, length of previous intubation, and the degree of hypoxemia adjudicated the selection of therapy modality. The failure rates were 17.6 and 11% at NIPPV and HFNC deliveries. A less than 10% decline in respiration within an hour, FiO₂ requirement >55% at the 6th hour, and a PRISM-3 score >8 were three independent risk factors related to NIV failure. Instead of patient demographics (age, sex, and nature of respiratory failure), therapy modality (NIPPV or HFNC) and the institution of NIV as a first-line or rescue therapy, the nature of the acute disease (sepsis and ARDS), prolonged intubation prior to NIV, and the use of nasal masks were associated with therapy.

Acknowledgment
Authors thank to Başak Oğuz YOLCULAR (Department of Biostatistics and Medical Informatics, Akdeniz University Faculty of Medicine, Antalya) for statistical analysis.
Informed consent
The study protocol was approved by Akdeniz University Faculty of Medicine, Clinical Research Ethics Committee (no: 70904504/525, date: 11.18.2016) and followed the principles for human investigations outlined in the Second Declaration of Helsinki. It was also registered at clinicaltrials.gov (approval number: 70904504/525).

References

1. Alpgiray B (2006) Determination of the effects of the canola oil on the performance and emission characteristics of the diesel engine. Master Thesis. Ankara University, Institute of Natural and Applied Sciences.

2. Keenan SP, Sinuff T, Burns KEA, Muscedere J, Kutsogiannis J et al. Clinical practice guidelines for the use of noninvasive positive-pressure ventilation and noninvasive continuous positive airway pressure in the acute care setting. Canadian Medical Association Journal 2011; 183 (3): 195-214. doi: 10.1503/cmaj.100671

3. Fioretto JR, Ribeiro CF, Carpi MF, Bonatto RC, Moraes MA et al. Comparison between noninvasive mechanical ventilation and standard oxygen therapy in children up to 3 years old with respiratory failure after extubation: a pilot prospective randomized clinical study. Pediatric Critical Care Medicine 2015; 16 (2): 124-130. doi: 10.1097/PCC.0000000000000309

4. Fedor KL. Noninvasive respiratory support in infants and children. Respiratory Care 2017; 62 (6): 699-717. doi: 10.4187/respcare.05244

5. Munoz-Bonet JI, Flor-Macian EM, Brines J, Roselló-Millet PM, Cruz Llopis M et al. Predictive factors for the outcome of noninvasive ventilation in pediatric acute respiratory failure. Pediatric Critical Care Medicine 2010; 11 (6): 675-680. doi: 10.1097/PCC.0b013e3181d8e303

6. Essouri S, Laurent M, Chevret L, Durand P, Haas V, Perot C et al. Physiological effects of noninvasive positive ventilation during acute moderate hypercapnic respiratory insufficiency in children. Intensive Care Medicine 2008; 34 (12): 2248-2255. doi: 10.1007/s00134-008-1202-9

7. Mayordomo-Colunga J, Medina A, Rey C, Menéndez S, Arcos ML et al. Non-invasive ventilation in pediatric asthma: a prospective observational study. Pediatric Pulmonology 2011; 46 (10): 949-955. doi: 10.1002/ppul.21466

8. Bonora JP, Frydman J, Retta A, Canepari A. Post-extubation non-invasive ventilation in the pediatric intensive care unit: a multicenter study. Archivos argentinos de pediatría 2018; 116 (5): 333-339. doi: 10.5546/aap.2018.eng333

9. Khirani S, Ramirez A, Aloui S, Leboulanger N, Picard A et al. Continuous positive airway pressure titration in infants with severe upper airway obstruction or bronchopulmonary dysplasia. Critical Care 2013; 17 (4): 167. doi: 10.1186/cc12846

10. Essouri S, Durand P, Chevret L, Haas V, Perot C et al. Physiological effects of noninvasive positive ventilation during acute moderate hypercapnic respiratory insufficiency in children. Intensive Care Medicine 2008; 34 (12): 2248-2255. doi: 10.1007/s00134-008-1202-9

11. Abadesso C, Nunes P, Silvestre C, Matias E, Loureiro H et al. Non-invasive ventilation in acute respiratory failure in children. Pediatric Reports 2012; 4 (2): 16. doi: 10.4081/pr.2012.e16

12. Mortamet G, Amaddeo A, Essouri S, Renolleau S, Emerauid G et al. Interfaces for noninvasive ventilation in the acute setting in children. Paediatric Respiratory Reviews 2017; 23: 84-88. doi: 10.1016/j.prrv.2016.09.004

13. Wang BC, Pei T, Lin CB, Guo R, Elashoff D et al. Clinical characteristics and outcomes associated with nasal intermittent mandatory ventilation in acute pediatric respiratory failure. World Journal of Critical Care Medicine 2018; 7 (4): 46-51. doi: 10.5492/wjccm.v7.i4.46

14. Morley SL. Non-invasive ventilation in paediatric critical care. Paediatric Respiratory Reviews 2016; 20: 24-31. doi: 10.1016/j.prrv.2016.03.001

15. Milesi C, Baleine J, Matecki S, Durand S, Combes C et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Medicine 2013; 39 (6): 1088-1094. doi: 10.1007/s00134-013-2879-y

16. Rochwerger B, Brochard L, Elliott MW, Hess D, Hill NS et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. European Respiratory Journal 2017; 50 (2): 1602426. doi: 10.1183/13993003.02426-2016

17. Morris JV, Ramnarayan P, Parslow RC, Fleming SJ. Outcomes for children receiving noninvasive ventilation as the first line mode of mechanical ventilation at intensive care admission: a propensity score-matched cohort study. Critical Care Medicine 2017; 45 (6): 1054-1053. doi: 10.1097/CCM.0000000000002369

18. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatric Critical Care Medicine 2015; 16 (5): 428-439. doi: 10.1097/PCC.0000000000002350

19. Feudtner, C Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatrics 2014; 14: 199. doi: 10.1186/1471-2431-14-199
20. Fleming S, Thompson M, Stevens R, Heneghan C, Plüddemann A et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet 2011; 377 (9770): 1011-1018. doi: 10.1016/S0140-6736(10)62226-X

21. Mayordomo-Colunga J, Pons M, López Y, José Solana M, Rey C et al. Predicting non-invasive ventilation failure in children from the SpO2/FiO2 (SF) ratio. Intensive Care Medicine 2013; 39 (6): 1095-1103. doi: 10.1007/s00134-013-2880-5

22. Bernet V, Hug MI, Frey B. Predictive factors for the success of noninvasive mask ventilation in infants and children with acute respiratory failure. Pediatric Critical Care Medicine 2005; 6 (6): 660-664. doi: 10.1097/01.pcc.0000170612.16938.f6

23. Dohna-Schwake C, Stehling F, Tschiedel E, Wallot M, Mellies U. Non-invasive ventilation on a pediatric intensive care unit: feasibility, efficacy, and predictors of success. Pediatric Pulmonology 2011; 46 (11): 1114-1120. doi: 10.1002/ppul.21482

24. Monaghan A. Detecting and managing deterioration in children. Paediatric Nursing 2005; 17 (1): 32-35. doi: 10.7748/pnad2005.02.17.1.32.c964

25. Bakalli I, Celaj E, Simaku A, Kola E, Sallabanda S. Predictors of noninvasive ventilation success in children with acute respiratory failure. Intensive Care Medicine 2015; 41 (5): 950-951. doi: 10.1007/s00134-015-3769-2

26. Mayordomo-Colunga J, Medina A, Rey C, Diaz JJ, Concha A et al. Predictive factors of noninvasive ventilation failure in critically ill children: a prospective epidemiological study. Intensive Care Medicine 2009; 35 (3): 527-536. doi: 10.1007/s00134-008-1346-7

27. Kelly GS, Simon HK, Sturm JJ. High-flow nasal cannula use in children with respiratory distress in the emergency department: predicting the need for subsequent intubation. Pediatric Emergency Care 2013; 29 (8): 888-892. doi: 10.1097/PEC.0b013e31829e7f2f

28. Mayfield S, Bogossian F, O’Malley L, Schibler A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. Journal of Paediatrics and Child Health 2014; 50 (5): 373-378. doi: 10.1111/jpc.12509

29. Hansen G, Hochman J, Garner M, Dmytrowich J, Holt T. Pediatric early warning score and deteriorating ward patients on high-flow therapy. Pediatrics International 2019; 61 (3): 278-283. doi: 10.1111/ped.13787

30. Yaman A, Kendirli T, Ödek Ç, Ateş C, Taşyapar N et al. Efficacy of noninvasive mechanical ventilation in prevention of intubation and reintubation in the pediatric intensive care unit. Journal of Critical Care 2016; 32:175-181. doi: 10.1016/j.jcrc.2015.12.013

31. Essouri S, Chevrelet L, Durand P, Haas V, Fauroux B et al. Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. Pediatric Critical Care Medicine 2006; 7 (4): 329-334. doi: 10.1097/01.PCC.0000225089.21176.0B

32. Bernet V, Hug MI, Frey B. Predictive factors for the success of noninvasive mask ventilation in infants and children with acute respiratory failure. Pediatric Critical Care Medicine 2005; 6 (6): 660-664. doi: 10.1097/01.pcc.0000170612.16938.f6

33. James CS, Hallewell CP, James DP, Wade A, Mok QQ. Predicting the success of non-invasive ventilation in preventing intubation and re-intubation in the paediatric intensive care unit. Intensive Care Medicine 2011; 37 (12): 1994-2001. doi: 10.1007/s00134-011-2386-y

34. Liu J, Bell C, Campbell V, DeBacker J, Tamberg E et al. Noninvasive ventilation in patients with hematologic malignancy: a retrospective study. Journal of Intensive Care Medicine 2019; 34 (3): 197-203. doi: 10.1177/0885066617690725

35. Fuchs H, Schoss J, Mendler MR, Lindner W, Hopfner R et al. The cause of acute respiratory failure predicts the outcome of noninvasive ventilation in immunocompromised children. Klinische Padiatrie 2015; 227 (6-7): 322-328. doi: 10.1055/s-0034-1395692

36. Hsiung Lee ES, Jiann Lim DT, Taculod JM, Sahagun JT, Otero JP et al. Factors associated with reintubation in an intensive care unit: a prospective observational study. Indian Journal of Critical Care Medicine 2017; 21 (3): 131-137. doi: 10.4103/ijccm.IJCCM_452_16

37. Peters MJ, Agbeko R, Davis P, Klein N, Zenasni Z et al. Randomized study of early continuous positive airways pressure in acute respiratory failure in children with impaired immunity (SCARF) ISRCTN82853500. Pediatric Critical Care Medicine 2018; 19 (10): 939-948. doi: 10.1097/PCC.0000000000001683

38. Chacur FH, Villela Felipe LM, Fernandes CG, Lazzarini LC. The total face mask is more comfortable than the oronasal mask in noninvasive ventilation but is not associated with improved outcome. Respiration 2011; 82 (5): 426-430. doi: 10.1159/000324441

39. Bergquist-Beringer S, Davidson J, Agosto C, Linde NK, Abel M et al. Evaluation of the national database of nursing quality indicators (NDNQI) training program on pressure ulcers. Journal of Continuing Education in Nursing 2009; 40 (6): 252-258. doi: 10.3928/00220124-20090522-05